New published clinical research on Univestin™ and AmLexin™ in combination has shown positive synergistic effects, for Osteoarthritis (OA) and overall joint health1. Studies show that these ingredients work effectively together to help reduce pain sensitivity while supporting the preservation of the articular cartilage matrix integrity composition.
The research highlights how the pairing of these two well-known US brands may provide a powerful, synergistic approach to joint support for healthy aging.
Moreover, both ingredients have scientific evidence proving their individual benefits. Univestin™ for its fast-acting effects by alleviating joint discomfort and stiffness within 3-7 days, and AmLexin™ for its effectiveness in articular cartilage support.
Research on Univestin™ has shown that doses of 250mg/day and 500mg/day were significantly more effective than the alternative drug (Celecoxib at 200mg/day) for reducing joint stiffness and joint function incapacity caused by OA2. Complementing this, AmLexin™ has clinical research showing that a dose of 400mg/day over 12 weeks, can significantly reduce uCTX-II (the most well-validated biomarker in osteoarthritis) by 8.9%, compared to alternative treatments3.
The results of this new research, and various individual studies on both ingredients, demonstrates how Univestin™ and AmLexin™ could potentially be an alternative, plant-based, natural solution for the management of OA and/or its associated symptoms, by enhancing the anti-inflammatory and analgesic action of Univestin™ with the cartilage degradation support from AmLexin™.
Innovations in Food (& Beverage) Technology is a quarterly magazine distributed globally both in Print and Digital formats. www.innovationsfood.com. Twitter: @Innovfoodtech. Instagram: @innovationsinfoodtechnology. Linkedin: www.linkedin.com/in/terry-prior52
